Effect of Glucagon-Like Peptide-I (GLP-I) Analogue in Patients with Stable Coronary Artery Disease With Left Ventricular Ejection Fraction ≤ 40 %. Principal Investigator: Wamiq Y Banday. M.B.B.S Sub Investigators: Howard Lippes, MD. Benjamin G. Rueda, MD. Aravind Herle, MD. Internal Medicine Training Program. Catholic Health System. SUNY at Buffalo. 2157 Main Street. Buffalo, NY 14214
51
Embed
Effect of Glucagon-Like Peptide-I (GLP- I) Analogue in Patients with Stable Coronary Artery Disease With Left Ventricular Ejection Fraction ≤ 40 %. Principal.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Effect of Glucagon-Like Peptide-I (GLP-I) Analogue in Patients with Stable Coronary Artery Disease With Left
Ventricular Ejection Fraction ≤ 40 %.
Principal Investigator: Wamiq Y Banday. M.B.B.S
Sub Investigators: Howard Lippes, MD.
Benjamin G. Rueda, MD.
Aravind Herle, MD.Internal Medicine Training Program. Catholic Health System.
SUNY at Buffalo. 2157 Main Street. Buffalo, NY 14214
Our Study
•Prospective•Single site•Non-randomized•Pilot study
Glucagon Like Peptide-1 • GLP-1 in a gut-derived incretin hormone that is
secreted in response to nutrients.
• It is a degradation product of pre-proglucagon molecule, a 179 amino acid residue, a product of single Glucagon gene.
• Gene is expressed in the Alpha-cells of pancreas, L-cells of Gut & neurons of the brainstem.
• GLP-1(7-36) is one of the 5 separately processed domains of pre-proglucagon. This is processed in the L-cells of the gut.
Pre-pro glucagon(179 amino acid)
BRAINPANCREAS
•Glucagon•MPGF
GUT
•GLP-1•GLP-2
•GLP-1 •GLP-1 (7-36)(Bio. Active) GLP-1 (9-36)
Agonis/antagonistFunction?
Dipetidyl peptidase-IV (DPP-IV)
GLP-1 Receptors & its effect.
Adapted from: T. Nystrom: Hormone Metabolism 2008:40
GLP-1 receptor • G-protein coupled receptor.
Figure 1.
FIG. 2.
GLP-1 contd• GLP-1 (7-36) is biologically active having both insulinomimetic
and insulinotropic activity.
• GLP-1 has glucoregulatory effects including
– Augmentation of glucose-stimulated insulin secretion
– Suppression of postprandial glucagon secretion
– Delayed gastric emptying
– Hypothalmic-mediated satiety of apetite.
– Primarily implicated in the control of appetite and satiety.
GLP-1 and Exenatide• Exenatide is a synthetic analogue of exendin-4
found in salivary secretion of Gila Monster, Heloderma suspectum- “Lizard spit”
• Exenatide, GLP-1 analogue, is a 39-residue reptilian peptide.
• It shares 53% of its amino acid sequence with mammilian GLP-1
• It is functionally similar to mammalian GLP-1.
• Half life of exenatide is 2.4 hrs vs. 1 -4 minute for GLP-1
Mean (SEM) Serum Insulin and Plasma glucose Concentration Following a One-time Injection of BYETTA or Placebo in Fasting Type-2 Diabetic
patient
Adapted from http://www.BYETTA.com
Bench to Bedside• Pancreatic type GLP-1 receptors are found in
lung, brain, kidney, stomach and Heart.• T. Nystrom Hor Metabolism Res. 2008
“Bench to Bedside” contd.• Bose et al, Diabetes 2005. GLP-1
infusion reduced the infarct size in isolated rat heart.
• Nikolaidis L A et al, J. Pharmacol Exp Ther, 2005. Limits the Myocardial stunning canines.
• Nikolaidis L A et al, Circulation 2004. LV function Improved in dogs with pacing induced DCM.
“Bench to Bedside” contd.• Nikolaidis L A et al, Circulation 2004.
Benefits of GLP-1 Infusion in patients with Severe LV dysfunction following Acute MI and reperfusion.
• George G. Sokos et al, Journal of Cardiac Failure . GLP-1 Infusion improves LV function, functional Status and quality of life in Severe heart failure patients
Myocardium, “Metabolic omnivore”
• Normal heart utilizes NEFAs (preferably), Glucose and lactate for the production ATP1,2
• Under stress –Myocardial infarction and CHF- it switches to Glucose preferably3
– Energetically more efficient.
– Less O2 requirement for ATP production.
• Metabolic adaption and flexibility by– Physiological changes and – Transcriptional mechanism41. AHA, Heart disease and Stroke staistics:2005;2003; 2. Taegtmeyer et al, Circulation
2002:105;1727-33; 3. Goodwin GW et al; J Biol Chem 1998;273;29530-29539; 4. Taegtmeyer et al, Circulation 2002;106; 2043-5
• Loss of metabolic flexibility exhibits-– Early metabolic dysregulation in failing heart1
– Features of insulin resistance 2,3
• Left Ventricular dysfunction results in – Myocardial insulin resistance as well as– Whole body insulin resistance
• Magnitude and cellular mechanism underlying myocardial insulin resistance demonstrated in concious dogs with DCM3
– Increased glucose utilization can improve Cardiac function.
• Giuseppa Paolisso et al demonstrated high norepinephrine levels associated with insulin resistance in in CHF patients4.
1. Taegtmeyer et al, ANN N Y Acad Sci, 2004;1015:1-12; 2. Shah A et al Rev A Cardiovasc Med. 2003 (suppl 6); S50-S57; 3. Nikolaidis L A et al, Cardiovascular Res 2004; 61: 297-306. 4. Metabolism 40:9:972-977,1991.
Over come insulin resistance and improve glucose Utilization
• Glucose-insulin-potassium (GIK) infusion has been used as an adjuvant to MI- mixed results.
• GIK infusion can’t be used in CHF- volume• GLP-1 has similar effects on glucose
metabolism.• GLP-1 has been effective in Acute MI1
1. Nikolaidis L A et al, circulation 200; 109:962-5
“Metabolic Kick” to Chronically Insulin-Resistant Myocardium
Hypothesis
We hypothesize that Exenatide, would improve myocardial glucose utilization and will
increase the Left ventricular ejection fraction in patients with stable ischemic
cardiomyopathy and LVEF </= 40%
•IRB proposal & Approval
•Protocol and • SITE
Material & Methods
SITE “A”ICD-9 Code,
MUGA
SITE “B”ICD-9 Code,
CHF
SITE “C”Manual
chart review
Site “A”350
Site “B”240
Site”C”120
45 16 2
No. Of patients Screened
No. Of patients Qualified
6 3 1PatientsAgreed
Total patients Enrolled 10
3 patients•2 Irregular rhythm•1 difficult venous
access
Total Patients Analyzed
Patients WithdrawnFrom study
7 patients
Baseline Assessment
•LVEF Assessment
•Blood Sugar
•Heart Rate•Systolic BP•Diastolic BP
•Mean Arterial BP
Multi gated Acquisition (MUGA) Scan
•Standard Protocol
•Portable OneTouch Ultra Glucometer
•Non-Invasive•Automatic DynaMax
Exenatide (Byetta) 5 mcg
Subcutaneous administered.
60 Minutes post Exenatide.
•LVEF Assessment
•Blood Sugar
•Heart Rate•Systolic BP•Diastolic BP
•Mean Arterial BP
Multi gated Acquisition (MUGA) Scan
•Standard Protocol
•Portable OneTouch Ultra Glucometer
•Non-Invasive•Automatic DynaMax
Monitoring•Heart Rate
•Blood Pressure( SBP,DBP & MAP)
•Blood Sugar
•30 minutes•60 minutes•90 minutes
Analysis of Ejection fraction of Pre & post Exenatide•Automatic, computerized
•Compared pre and post Exenatide
Calculated:• Primary End Point
•Secondary End Points•Patients acted there own controls
•Computer out put was manually analyzed•Reader was blinded
Compliance with HIPAA
Statistical analysis
• SPSS software• Paired t-test• Independent t-test• Mean ± SEM• P-value(2-tailed) and <0.05 was
statistically significant.
Table: Patient DemographicNo. Of patients 7
Age (yrs) 70 3
Male, N (%) 5 (71.4)
Female 2 (28.5)
Weight (kgs) 94 9.2
BMI (kg/m2) 30.5 3.2
SBP (mmHg) 125 4
DBP (mmHg) 73.4 4.26
MAP (mmHg) 88.2 4.182
Heart rate (beats/min.) 73 5.34
Regular rhythm, N (%) 7 (100)
Diabetes , N (%) 4 (57)
Hypertension, N (%) 3 (43)
Coronary artery disease, N (%) 7(100)
BMI, Body mass index; SBP, Systolic blood pressure; DBP, diastolic blood pressure; MAP, Mean arterial pressure;